An antiviral drug from the Gilead Sciences, Remdesivir, is also approved in Japan. (Image via SINDOnews)

Japan ready to get Remdesivir, how about Avigan?

On Thursday, the Japanese government decided to approve the antiviral drug developed by Gilead Sciences, Remdesivir, from the United States (U.S). The drug is approved to treat the patients of the novel coronavirus disease (COVID-19). This month, the Japanese government is aiming to approve its home-grown antiviral drug called Avigan.

The decision made Japan the second country to approve the drug after the U.S Food and Drug Administration (FDA) approved it on 1 May for emergency use against severe cases of COVID-19.

The Prime Minister of Japan, Shinzo Abe, stated last week that the Japanese government was preparing to accelerate the approval for the antiviral drug developed by the U.S firm. Previously, the U.S saw that the clinical trial of Remdesivir showed an acceleration of recovery time in some COVID-19 patients by a third. However, the difference in mortality rate was not statistically significant.

Remdesivir is administered by injection and was available to some patients who joined the clinical trials around the world.

How about Avigan? The antiviral drug developed by the Japanese medical firm, Fujifilm Toyama Chemical? The Chief Cabinet Secretary, Yoshihide Suga, stated that the government aims to approve the antiviral drug in May. That is if the clinical trial on 100 patients proves the drug effective. Also called Favipiravir, Avigan was used to be used in Japan in 2014 to treat flu.

Avigan is not commercially sold and can only be produced and distributed at the request of the Japanese government. Administered as a pill, Avigan blocks the ability of a virus to replicate inside a cell. Compared to Avigan, Remdesivir merges itself into a virus’s genome, disrupting its replication process.

On a side note, Avigan affects fetal development as shown in animal studies. Therefore, it is wise to not prescribe Avigan for pregnant women.

Source: https://bit.ly/35H6nj4